Repligen (RGEN)
(Delayed Data from NSDQ)
$135.00 USD
+12.40 (10.11%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $135.03 +0.03 (0.02%) 7:38 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$135.00 USD
+12.40 (10.11%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $135.03 +0.03 (0.02%) 7:38 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Zacks News
Repligen (RGEN) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Misses Q2 Earnings Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of -11.11% and 3.62%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Repligen (RGEN)
by Zacks Equity Research
Repligen Corporation (RGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Should You Sell Repligen Corporation (RGEN) Before Earnings?
by Zacks Equity Research
Repligen Corporation (RGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
5 Biotech Stocks Well Poised to Surpass Expectations in Q3
by Zacks Equity Research
The pharma and biotech industry has demonstrated strength
Top Ranked Momentum Stocks to Buy for July 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 3rd:
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
3 Overlooked Drug Stocks to Watch Out for in 2017
by Arpita Dutt
As we start the New Year, here is a look at 3 drug stocks that have not been in the news much but have been witnessing upward estimate revisions and sport a strong Zacks Rank.
Get Ready To Be Surprised This Earnings Season
by Kevin Matras
Kevin Matras details a good screen to use before and after a company reports this earnings season. Highlighted stocks include BANR, RGEN, RNF, RYL and TGI.
Top Stocks with Big Potential Catch-Up Moves
by Kevin Matras
Kevin Matras shows how to find the top stocks in the top sectors with the biggest potential catch-up price moves. Highlighted stocks include ADS, GIL, LGF, RGEN and WRLD.